 Applications Market.png)
Healthcare is changing. It is becoming more focused on each individual person. Doctors and researchers now want to know how diseases and treatments work in real life. This is where real-world evidence (RWE) helps. RWE comes from everyday sources and shows what’s truly happening with patients outside controlled settings.
Genomic data is now an essential part of RWE. This blog explains what genomic datasets are and how they support real-world data. It also covers why the genomic data set for real world evidence (RWE) applications market is becoming an essential part of healthcare.
Understanding Genomic Datasets
Genomic datasets are collections of information about the genes of a person. This information can come from full DNA tests and smaller gene panels. Genomic data can also be obtained from specific tests used to check certain health conditions.
In simpler terms, genomic data helps us understand:
- Why do some people get sick while others stay healthy
- Why does a medicine work well for one person and not for the other
- How a person’s genes interact with their lifestyle and environment
The usefulness of these datasets increases when they are combined with real-world evidence. This includes everyday health information such as medical records or lab results. Together, they give a more complete picture of a person’s health.
What Are Key Market Stats?
The genomic data set for real world evidence applications market is projected to witness sustained growth. The market is expected to witness a CAGR of 15.2% from 2024 to 2032. It is anticipated to reach USD 1,704.60 million by 2032.
How Genomic Data Fits into RWE?
Traditionally, real-world evidence came from medical records and patient surveys. These sources are useful. But they don’t explain why diseases behave a certain way. Or why treatments work differently for different people. This is where genomic data makes a big difference.
It provides researchers with the ability to study a person’s genes and compare them with real-life health results. This allows them to better understand:
- How diseases develop over time
- Why some treatments don’t work for certain projects
- Which people are likely to benefit from specific therapies
- How to identify symptoms before they appear
Why Genomic Data and RWE Are Important?
More Accurate Diagnosis
People often don’t show the same symptoms for the same illness. Some feel mild discomfort. Others may have complications. Genomic data helps doctors uncover hidden genetic reasons behind these differences. Pairing this with real-world medical records makes diagnoses clearer.
Personalized Treatment Decisions
Modern healthcare aims at finding the right treatment for the right person. Genomic data helps doctors understand how a person’s body responds to medicines. It shows how drugs are processed and how likely side effects are. RWE adds another layer by showing how people with similar traits responded in everyday clinical settings.
Early Detection and Prevention
Genomic data can highlight health risks before symptoms show up. For example, certain gene markers can show a higher chance of developing cancers or metabolic issues. The addition of details by RWE allows doctors to get a complete picture of someone’s risks.
Who Are Top Genomic RWE Data Providers?
Caris Life Sciences
Caris Life Sciences uses its extensive genomic dataset to generate RWE. The company’s RWE primarily focuses on oncology, the personalized medicine market, and clinical decision-making. The Caris dataset is one of the largest in oncology. It is generated from millions of tests and comprises over 60 petabytes of oncology-specific data. Caris leverages this large-scale dataset through its AI platform, Caris CODEai, to derive novel insights.
Guardant Health
Guardant Health provides access to a large and multimodal clinical-genomic real-world data (RWD) solution called GuardantINFORM. The solution integrates various data types to provide a comprehensive view of the patient journey. The genomic data is collected using the company’s extensive liquid and tissue biopsy tests. It covers over 60 solid tumor cancer types and more than 450,000 unique patients.
Foundation Medicine, Inc.
FMI is a leading player in the genomic dataset for real-world evidence applications market. The company’s Clinico-Genomic Database (CGDB) is a large-scale dataset. It links de-identified comprehensive genomic profiling (CGP) data with de-identified real-world clinical outcomes data from EHR solutions from the electronic health records market. The data sets are primarily used in oncology to understand etiology and stratify patients.
HealthVerity, Inc
HealthVerity, Inc. offers access to genomic data as part of its RWD ecosystem for RWE applications. The company’s data ecosystem includes laboratory data from major providers such as Labcorp. It uses its Identity Manager and the HealthVerity ID (HVID) to de-identify patients and link disparate data sources. The linked data supports life science companies in improving clinical trials and making regulatory submissions.
Invitae Corporation
Invitae Corporation is a major company in the genomic data set for real world evidence applications market. It makes use of its vast genomic and clinical data for RWE. The company prioritizes privacy and control over its genetic data. Patients can use the Invitae patient portal to set or change their preferences regarding data sharing for research. Researchers who want to access the data for a study typically have to go through a formal request process.
What Trends Are Shaping Market Landscape?
Growing National Genomic Projects
More countries are starting big genomic sequencing programs. These collect DNA data from many different groups of people. As such, more diverse data sets are created, making RWE studies more inclusive.
More Patient-Controlled Platforms
People today want better control over their medical information. New platforms now allow patients to safely share their genomic data. This makes it easier for doctors and patients to work together.
Shift Towards Preventive Care
Healthcare is shifting towards early prevention of problems. Combining genomic insights with real-world data allows doctors to spot risks sooner. It also allows them to design care plans that fit the needs of every patient.
Conclusion
Genomic data sets combined with RWE are changing how healthcare works. They have made it possible for doctors to understand how diseases and treatments affect people in their everyday lives. As more hospitals start using genomic tools, the connection between genetic information and daily health data is expected to become stronger. The key players in the genomic data set for real world evidence applications market are expected to focus on strategic developments to drive growth.
.png)
